Henry Schein, Inc. (NASDAQ:HSIC) Shares Bought by Gabelli Funds LLC

Gabelli Funds LLC raised its position in Henry Schein, Inc. (NASDAQ:HSICGet Rating) by 6.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 351,136 shares of the company’s stock after acquiring an additional 20,500 shares during the quarter. Gabelli Funds LLC’s holdings in Henry Schein were worth $27,224,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Prospector Partners LLC grew its position in Henry Schein by 6.7% in the 4th quarter. Prospector Partners LLC now owns 43,300 shares of the company’s stock valued at $3,357,000 after acquiring an additional 2,700 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Henry Schein by 2.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,041,818 shares of the company’s stock worth $80,772,000 after buying an additional 25,266 shares in the last quarter. Ensign Peak Advisors Inc grew its position in shares of Henry Schein by 184.0% during the fourth quarter. Ensign Peak Advisors Inc now owns 44,314 shares of the company’s stock worth $3,436,000 after buying an additional 28,711 shares in the last quarter. Equitable Holdings Inc. grew its position in shares of Henry Schein by 15.8% during the fourth quarter. Equitable Holdings Inc. now owns 11,000 shares of the company’s stock worth $853,000 after buying an additional 1,500 shares in the last quarter. Finally, Covestor Ltd acquired a new position in shares of Henry Schein during the fourth quarter worth about $35,000. 94.30% of the stock is owned by institutional investors.

In other news, Director Scott Philip Serota acquired 1,000 shares of Henry Schein stock in a transaction on Friday, March 4th. The stock was bought at an average price of $85.87 per share, for a total transaction of $85,870.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Walter Siegel sold 15,070 shares of the business’s stock in a transaction that occurred on Friday, May 6th. The shares were sold at an average price of $82.97, for a total value of $1,250,357.90. Following the completion of the sale, the vice president now owns 40,122 shares of the company’s stock, valued at approximately $3,328,922.34. The disclosure for this sale can be found here. In the last quarter, insiders sold 60,257 shares of company stock valued at $5,036,317. 1.00% of the stock is owned by company insiders.

HSIC stock traded up $0.58 during trading on Friday, hitting $83.45. 780,785 shares of the company’s stock were exchanged, compared to its average volume of 1,032,310. The company has a current ratio of 1.79, a quick ratio of 0.91 and a debt-to-equity ratio of 0.18. Henry Schein, Inc. has a 52-week low of $70.25 and a 52-week high of $92.68. The business has a 50-day moving average price of $86.93 and a two-hundred day moving average price of $81.06. The stock has a market capitalization of $11.52 billion, a price-to-earnings ratio of 18.14, a PEG ratio of 1.45 and a beta of 0.75.

Henry Schein (NASDAQ:HSICGet Rating) last issued its quarterly earnings data on Tuesday, May 3rd. The company reported $1.30 earnings per share for the quarter, beating analysts’ consensus estimates of $1.21 by $0.09. Henry Schein had a return on equity of 15.70% and a net margin of 5.11%. The company had revenue of $3.18 billion during the quarter, compared to analysts’ expectations of $3.12 billion. During the same quarter in the previous year, the business earned $1.24 earnings per share. The firm’s revenue for the quarter was up 8.7% on a year-over-year basis. On average, equities research analysts anticipate that Henry Schein, Inc. will post 4.86 earnings per share for the current fiscal year.

A number of equities analysts have recently commented on HSIC shares. Barrington Research boosted their price objective on Henry Schein from $96.00 to $102.00 in a research report on Wednesday, February 16th. Credit Suisse Group boosted their price objective on Henry Schein from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 16th. Morgan Stanley boosted their price objective on Henry Schein from $67.00 to $72.00 and gave the stock an “underweight” rating in a research report on Wednesday, February 16th. StockNews.com began coverage on Henry Schein in a research note on Thursday, March 31st. They set a “buy” rating for the company. Finally, Zacks Investment Research upgraded Henry Schein from a “sell” rating to a “hold” rating and set a $91.00 target price for the company in a research note on Thursday, May 5th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $93.83.

About Henry Schein (Get Rating)

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

Featured Stories

Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSICGet Rating).

Institutional Ownership by Quarter for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.